Candida Species Distribution and Antifungal Susceptibility Testing According to EUCAST and New vs. Old CLSI Clinical Breakpoints: a Six-Year Prospective Candidemia Survey from the Fungal Infection Network of Switzerland (FUNGINOS).

Details

Serval ID
serval:BIB_E67E241BAEB4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Candida Species Distribution and Antifungal Susceptibility Testing According to EUCAST and New vs. Old CLSI Clinical Breakpoints: a Six-Year Prospective Candidemia Survey from the Fungal Infection Network of Switzerland (FUNGINOS).
Journal
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Author(s)
Orasch C., Marchetti O., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Rossi M., Pfyffer G., Ruef C., Fehr J., Zbinden R., Calandra T., Bille J.
Working group(s)
The Fungal Infection Network of Switzerland (FUNGINOS)
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Publication state
Published
Issued date
2013
Language
english
Notes
Publication types: JOURNAL ARTICLE
Publication Status: aheadofprint
Abstract
We analyzed the species distribution of Candida blood isolates (CBI), prospectively collected between 2004 and 2009 within FUNGINOS, and compared their antifungal susceptibility according to clinical breakpoints defined by: EUCAST in 2013, CLSI in 2008 (old CLSI breakpoints) and 2012 (new CLSI breakpoints). CBI were tested for susceptiblity to fluconazole, voriconazole and caspofungin by microtitre broth dilution (Sensititre(®) YeastOne(TM) test panel). Of 1090 CBI, 675 (61.9%) were C. albicans, 191 (17.5%) C. glabrata, 64 (5.9%) C. tropicalis, 59 (5.4%) C. parapsilosis, 33 (3%) C. dubliniensis, 22 (2%) C. krusei and 46 (4.2%) rare Candida species. Independently of the breakpoints applied, C. albicans was almost uniformely (>98%) susceptible to all 3 antifungal agents. In contrast, the proportions of fluconazole- and voriconazole- susceptible C. tropicalis and F-susceptible C. parapsilosis were lower according to EUCAST/new CLSI breakpoints than to the old CLSI breakpoints. For caspofungin, non-susceptibility occurred mainly in C. krusei (63.3%) and C. glabrata (9.4%). Nine isolates (5 C. tropicalis, 3 C. albicans, 1 C. parapsilosis) were cross-resistant to azoles according to EUCAST breakpoints compared to 3 isolates (2 C. albicans, 1 C. tropicalis) according to new and 2 (2 C. albicans) to old CLSI breakpoints. Four species (C. albicans, C. glabrata, C. tropicalis, C. parapsilosis) represented >90% of all CBI. In vitro resistance to fluconazole, voriconazole and caspofungin was rare among C. albicans, but an increase of non-susceptibile isolates was observed among C. tropicalis/C. parapsilosis for the azoles and C. glabrata/C. krusei for caspofungin according to EUCAST and new CLSI breakpoints compared to old CLSI breakpoints. This article is protected by copyright. All rights reserved.
Pubmed
Open Access
Yes
Create date
14/01/2014 16:26
Last modification date
18/09/2020 5:26
Usage data